⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALZN News
Alzamend Neuro, Inc. Common Stock
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Form 8-K
sec.gov
ALZN
Form 8-K
sec.gov
ALZN
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
prnewswire.com
ALZN
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
prnewswire.com
ALZN
Form 8-K
sec.gov
ALZN
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
prnewswire.com
ALZN
Form 8-K
sec.gov
ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
prnewswire.com
ALZN